J07B
VIRAL VACCINES
Наименование на групата: WHO Collaborating Centre for Drug Statistics Methodology
Подгрупи
ATC класификацията е дърво. Тази категория се разделя на 11 подгрупи.
-
J07BAEncephalitis vaccines 4 -
J07BBInfluenza vaccines 19 -
J07BCHepatitis vaccines 12 -
J07BDMeasles vaccines 4 -
J07BGRabies vaccines 3 -
J07BHRota virus diarrhea vaccines 2 -
J07BKVaricella zoster vaccines 2 -
J07BLYellow fever vaccines 1 -
J07BMPapillomavirus vaccines 3 -
J07BNCovid-19 vaccines 6 -
J07BXOther viral vaccines 8
Лекарствени продукти в тази категория
63 продукта в тази категория и подгрупите ѝ.
| Търговско име | Концентрация |
|---|---|
| Abrysvo | --¹ After reconstitution, one dose (0.5 mL) contains: RSV subgroup A stabilised prefusion F antigen*,** 60 micrograms RSV subgroup B stabilised prefusion F antigen*,** 60 micrograms * glycoprotein F stabilised in the prefusion conformation ** produced in Chinese Hamster Ovary cells by recombinant DNA technology |
| Adjupanrix | --¹ After mixing, 1 dose (0.5 ml) contains: Split influenza virus, inactivated, containing antigen* equivalent to: A/VietNam/1194/2004 (H5N1) like strain used (NIBRG-14) 3.75 μg** * propagated in eggs ** haemagglutinin AS03 adjuvant composed of squalene (10.69 mg), DL-alfa-tocopherol (11.86 mg) and polysorbate 80 (4.86 mg) |
| Aflunov | --¹ Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strain: A/turkey/Turkey/1/2005 (H5N1) - like strain (NIBRG-23) (clade 2.2.1) 7.5 micrograms** per 0.5 ml dose * propagated in fertilised hens’ eggs from healthy chicken flocks ** expressed in microgram haemagglutinin Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams |
| Ambirix | --¹ 1 dose (1 ml) contains: Hepatitis A virus (inactivated)¹,² 720 ELISA Units Hepatitis B surface antigen³,⁴ 20 micrograms ¹Produced on human diploid (MRC-5) cells ²Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al³+ ³Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology ⁴Adsorbed on aluminium phosphate 0.4 milligrams Al³+ |
| Anti - CHF Vaccine | suspension for injection. |
| AREXVY | --¹ After reconstitution, one dose (0.5 mL) contains: RSVPreF3¹ antigen²,³ 120 micrograms ¹ Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation = RSVPreF3 ² RSVPreF3 produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology ³ adjuvanted with AS01E containing: plant extract Quillaja saponaria Molina, fraction 21 (QS-21) 25 micrograms 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota 25 micrograms |
| Avaxim 160U adult | 0,5 ml |
| Avaxim 80U Pediatric | 0,5 ml |
| BIMERVAX | --¹ One dose (0.5 mL) contains: 40 micrograms of selvacovatein adjuvanted with SQBA (EU/1/22/1709/001-004). Selvacovatein is a SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351 and B.1.1.7 strains) produced by recombinant DNA technology using a plasmid expression vector in a CHO cell line. SQBA adjuvant containing per 0.5 mL dose: squalene (9.75 mg), polysorbate 80 (1.18 mg), sorbitan trioleate (1.18 mg), sodium citrate (0.66 mg), citric acid (0.04 mg) and water for injections. |
| Celldemic | --¹ One dose (0.5 ml) contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of strain*: A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) 7.5 micrograms** * propagated in Madin Darby Canine Kidney (MDCK) cells ** expressed in micrograms haemagglutinin. Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams |
| Cervarix | --¹ 1 dose (0.5 ml) contains: Human Papillomavirus1 type 16 L1 protein²,³,⁴ 20 micrograms Human Papillomavirus1 type 18 L1 protein²,³,⁴ 20 micrograms 1Human Papillomavirus = HPV ²adjuvanted by AS04 containing: 3-O-desacyl-4’- monophosphoryl lipid A (MPL)³ 50 micrograms ³ adsorbed on aluminium hydroxide, hydrated (Al(OH)₃) 0.5 milligrams Al³+ in total ⁴L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived from Trichoplusia ni. |
| COMIRNATY | -¹⁵ COMIRNATY JN.1 30 micrograms/dose dispersion for injection (EU/1/20/1528/028-031, EU/1/20/1528/043): 1 dose (0.3 mL) contains 30 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles). Bretovameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1). |
| Efluelda | Efluelda suspеnsion for injection in pre-filled syringe |
| Efluelda Tetra | suspеnsion for injection in pre-filled syringe |
| Engerix В | 0,5 ml |
| Engerix В | 1 ml |
| Ervebo | --¹ One dose (1 mL) contains: Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP¹² live, attenuated) ≥72 million pfu³ ¹Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP) ²Produced in Vero cells ³pfu= plaque-forming units |
| Fendrix | --¹ 1 dose (0.5 ml) contains: Hepatitis B surface antigen¹,²,³ 20 micrograms ¹adjuvanted by AS04C containing: - 3-O-desacyl-4’- monophosphoryl lipid A (MPL)² 50 micrograms ²adsorbed on aluminium phosphate (0.5 milligrams Al³+ in total) ³produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology |
| Fluad | --¹ Each 0.5 ml dose contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains*: A/Missouri/11/2025 (H1N1)pdm09-like strain (A/Missouri/11/2025, IVR-279) 15 micrograms HA** A/Darwin/1454/2025 (H3N2)-like strain (A/Michigan/105/2025, IVR-285) 15 micrograms HA** B/Tokyo/EIS13-175/2025-like strain (B/Tokyo/EIS13-175/2025, wild type) 15 micrograms HA** *propagated in fertilised hens’ eggs from healthy chicken flocks and adjuvanted with MF59C.1 **haemagglutinin |
| Fluarix | — |
| Fluarix Tetra | suspension for injection in pre-filled syringe |
| Flucelvax | --¹ Each 0.5 ml dose contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains*: A/Missouri/11/2025 (H1N1)pdm09-like strain (A/Tasmania/318/2025, CVR-351) 15 micrograms HA** A/Darwin/1415/2025 (H3N2)-like strain (A/Tasmania/787/2025, CVR-388) 15 micrograms HA** B/Pennsylvania/14/2025-like strain (B/Arizona/21/2025, wild type) 15 micrograms HA** * propagated in Madin Darby Canine Kidney (MDCK) cells ** haemagglutinin |
| Fluenz | --¹ 1 dose (0.2 ml) contains: Reassortant influenza virus* (live attenuated) of the following three strains**: A/Missouri/11/2025 (H1N1) pdm09-like strain (A/Switzerland/6849/2025, MEDI 400592) 10⁷.⁰±⁰.⁵ FFU*** A/Darwin/1454/2025 (H3N2)-like strain (A/Darwin/1369/2025, MEDI 406666) 10⁷.⁰±⁰.⁵ FFU*** B/Tokyo/EIS13-175/2025-like strain (B/Perth/115/2025, MEDI 407730) 10⁷.⁰±⁰.⁵ FFU*** * Propagated in fertilised hens’ eggs from healthy chicken flocks. ** Produced in VERO cells by reverse genetic technology. This product contains genetically modified organisms (GMOs). *** Fluorescent Focus Units. |
| Foclivia | 15 µg/ml |
| Gardasil | --¹ 1 dose (0.5 ml) contains approximately: Human Papillomavirus¹ Type 6 L1 protein², ³ 20 µg Human Papillomavirus¹ Type 11 L1 protein², ³ 40 µg Human Papillomavirus¹ Type 16 L1 protein², ³ 40 µg Human Papillomavirus¹ Type 18 L1 protein², ³ 20 µg ¹ Human Papillomavirus = HPV ² L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology ³ adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (225 micrograms Al) |
| Gardasil 9 | --¹ 1 dose (0.5 ml) contains approximately: Human Papillomavirus¹ Type 6 L1 protein²,³ 30 micrograms Human Papillomavirus¹ Type 11 L1 protein²,³ 40 micrograms Human Papillomavirus¹ Type 16 L1 protein²,³ 60 micrograms Human Papillomavirus¹ Type 18 L1 protein²,³ 40 micrograms Human Papillomavirus¹ Type 31 L1 protein²,³ 20 micrograms Human Papillomavirus¹ Type 33 L1 protein²,³ 20 micrograms Human Papillomavirus¹ Type 45 L1 protein²,³ 20 micrograms Human Papillomavirus¹ Type 52 L1 protein²,³ 20 micrograms Human Papillomavirus¹ Type 58 L1 protein²,³ 20 micrograms ¹ Human Papillomavirus = HPV ² L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology ³ adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.5 milligrams Al) |
| Havrix 1440 | suspension for injection (adult dose) |
| Havrix 720 | suspension for injection (junior monodose) |
| HBVAXPRO | 5 µg/0.5 ml |
| HEPLISAV B | --¹ One dose (0.5 mL) contains: Hepatitis B surface antigen¹,² 20 µg ¹Adjuvanted with 3000 micrograms 1018 adjuvant, a 22-mer immunostimulatory sequence oligonucleotide ²Produced in Hansenula polymorpha yeast cells by recombinant DNA technology |
| IMVANEX | --¹ Virus titer no less than of 5 x 10⁷ Inf.U One dose (0.5 ml) contains: Modified Vaccinia Ankara – Bavarian Nordic Live virus no less than 5 x 10⁷ Inf.U * *infectious units Produced in chick embryo cells |
| Incellipan | --¹ One dose (0.5 ml) contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of strain*: A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) 7.5 micrograms** * propagated in Madin Darby Canine Kidney (MDCK) cells ** expressed in micrograms haemagglutinin. Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams |
| Influvac | Influvac suspension for injection in pre-filled syringe |
| Influvac Tetra | suspension for injection in pre-filled syringe |
| IXCHIQ | --¹ After reconstitution, one dose (0.5 ml) contains: Chikungunya virus (CHIKV) Δ5nsP3 strain (live, attenuated)* not less than 3.0 log₁₀ TCID₅₀** *Produced in Vero cells ** 50% tissue culture infectious dose |
| Ixiaro | --¹ 1 dose (0.5 ml) contains: Japanese encephalitis virus strain SA₁₄-14-2 (inactivated)¹-² 6 AU³ corresponding to a potency of ≤ 460 ng ED₅₀ ¹ produced in Vero cells ² adsorbed on aluminium hydroxide, hydrated (approximately 0.25 milligrams Al³+) ³ Antigen Units |
| Kostaive | --¹ After reconstitution with 10 mL of sterile 0.9% Sodium Chloride Injection, one dose (0.5 mL) contains 5 micrograms of Zapomeran, a COVID-19 mRNA (encapsulated in lipid nanoparticles). Zapomeran is a single-stranded, 5'-capped messenger RNA (mRNA) replicon (self-amplifying mRNA), produced using a cell-free in vitro transcription from the corresponding DNA templates encoding a replicase and the spike glycoprotein of the G clade D614G variant of SARS-CoV-2. |
| mCOMBRIAX | --¹ One dose (0.32 mL) contains 31.7 micrograms of total RNA. mCOMBRIAX is single stranded, 5’-capped messenger RNAs (mRNAs) produced using a cell-free in vitro transcription from the corresponding DNA template, encoding seasonal influenza haemagglutinin (HA) glycoproteins: A/H1N1, A/H3N2, B/Victoria, and the linked N terminal domain and receptor-binding domain of the viral spike (S) protein of SARS CoV 2. Influenza virus strains and SARS CoV 2 composition per 0.32 mL dose: A/Wisconsin/67/2022 (A/H1N1 pdm09) .................…………………............8.3 micrograms RNA A/Darwin/6/2021 (A/H3N2) ..................................………………..............8.3 micrograms RNA B/Austria/1359417/2021 (B/Victoria lineage) ......................................8.3 micrograms RNA SARS CoV 2 Omicron XBB.1.5 ...........................................................6.7 micrograms RNA |
| M-M-RvaxPro | --¹ After reconstitution, one dose (0.5 ml) contains: Measles virus**¹ Enders' Edmonston strain (live, attenuated) not less than 1x10³ CCID50* Mumps virus**¹ Jeryl Lynn™ [Level B] strain (live, attenuated) not less than 12.5x10³ CCID50* Rubella virus**² Wistar RA 27/3 strain (live, attenuated) not less than 1x10³ CCID50* *50% tissue culture infectious dose **¹ Produced in chick embryo cells. **² Produced in WI-38 human diploid lung fibroblasts. |
| mNEXSPIKE | --¹ One dose (0.2 mL) contains 10 micrograms of SARS-CoV-2 mRNA. mNEXSPIKE is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA template, encoding the N-terminal domain and receptor-binding domain of the viral spike (S) protein of SARS-CoV-2 (XBB.1.5). |
| mRESVIA | --¹ One dose (0.5 mL) contains 50 micrograms of RSV mRNA (nucleoside modified) encapsulated in lipid nanoparticles. |
| Nuvaxovid | --¹ One dose (0.5 ml) contains 5 µg of the of SARS-CoV-2 spike protein* and is adjuvanted with Matrix-M. Adjuvant Matrix-M containing per 0.5 mL dose: Fraction-A (42.5 µg) and Fraction-C (7.5 µg) of Quillaja saponaria Molina extract. * produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the Spodoptera frugiperda species. |
| Pandemic influenza vaccine H5N1 AstraZeneca | --¹ 1 dose (0.2 ml) contains: Reassortant influenza virus* (live attenuated) of the following strain***: A/Vietnam/1203/2004 (H5N1) strain (A/Vietnam/1203/2004, MEDI 0141000136) 10⁷.⁰±⁰.⁵ FFU** * propagated in fertilised hens’ eggs from healthy chicken flocks. ** produced in VERO cells by reverse genetic technology. This product contains a genetically modified organism (GMO). *** fluorescent focus units |
| Priorix | powder and solvent for solution for injection |
| Priorix-Tetra | powder and solvent for solution for injection |
| ProQuad | --¹ After reconstitution, one dose (0.5 ml) contains: Measles virus¹ Enders’ Edmonston strain (live, attenuated) not less than 3.00 log10 CCID50* Mumps virus¹ Jeryl Lynn™ (Level B) strain (live, attenuated) not less than 4.30 log10 CCID50* Rubella virus² Wistar RA 27/3 strain (live, attenuated) not less than 3.00 log10 CCID50* Varicella virus³ Oka/Merck strain (live, attenuated) not less than 3.99 log10 PFU** *50% cell culture infectious dose **plaque-forming units ¹ Produced in chick embryo cells. ² Produced in human diploid lung (WI-38) fibroblasts. ³ Produced in human diploid (MRC-5) cells. |
| Qdenga | --¹ After reconstitution, 1 dose (0.5 mL) contains: Dengue virus serotype 1 (live, attenuated)*: ≥ 3.3 log10 PFU**/dose Dengue virus serotype 2 (live, attenuated)#: ≥ 2.7 log10 PFU**/dose Dengue virus serotype 3 (live, attenuated)*: ≥ 4.0 log10 PFU**/dose Dengue virus serotype 4 (live, attenuated)*: ≥ 4.5 log10 PFU**/dose *Produced in Vero cells by recombinant DNA technology. Genes of serotype-specific surface proteins engineered into dengue type 2 backbone #Produced in Vero cells by recombinant DNA technology **PFU = Plaque-forming units |
| Rabipur | — |
| Rabipur | — |
| Rotarix | --¹ not less than 10⁶·⁰ CCID₅₀ |
| RotaTeq | --¹ One dose (2 ml) contains: Rotavirus type* G1 not less than 2.2 x 10⁶ IU¹, ² Rotavirus type* G2 not less than 2.8 x 10⁶ IU¹, ² Rotavirus type* G3 not less than 2.2 x 10⁶ IU¹, ² Rotavirus type* G4 not less than 2.0 x 10⁶ IU¹, ² Rotavirus type* P1A[8] not less than 2.3 x 10⁶ IU¹, ² * Human-bovine rotavirus reassortants (live), produced in Vero cells. ¹ Infectious Units ² As lower confidence limit (p = 0.95) |
| Shingrix | --¹ After reconstitution, one dose (0.5 mL) contains: Varicella Zoster Virus¹ glycoprotein E antigen²,³ 50 micrograms ¹ Varicella Zoster Virus = VZV ² adjuvanted with AS01B containing: plant extract Quillaja saponaria Molina, fraction 21 (QS-21) 50 micrograms 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota 50 micrograms ³ glycoprotein E (gE) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology |
| Spikevax | --⁶ One dose (0.5 mL) contains 50 micrograms of SARS-CoV-2 JN.1 mRNA, a COVID-19 mRNA Vaccine (nucleoside modified) (embedded in lipid nanoparticles). One dose (0.25 mL) contains 25 micrograms of SARS-CoV-2 JN.1 mRNA, a COVID-19 mRNA Vaccine (nucleoside modified) (embedded in lipid nanoparticles). SARS-CoV-2 JN.1 mRNA is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (JN.1). |
| Stamaril | powder and solvent for suspension for injection |
| Supemtek | --¹ One dose (0.5 ml) contains: Influenza virus haemagglutinin (HA) proteins, of the following strains*: A/California/07/2009 (H1N1)pdm09-like strain (A/California/07/2009) 45 micrograms HA A/Texas/50/2012 (H3N2)-like strain (A/Texas/50/2012) 45 micrograms HA B/Brisbane/60/2008-like strain (B/Brisbane/60/2008) 45 micrograms HA * produced by recombinant DNA technology using a baculovirus expression system in a continuous insect cell line that is derived from Sf9 cells of the fall armyworm, Spodoptera frugiperda. |
| Supemtek Tetra | --¹ One dose (0.5 mL) contains: Influenza virus haemagglutinin (HA) proteins, of the following strains*: A/XXXXXX (H1N1).................................. 45 micrograms HA A/XXXXXX (H3N2).................................. 45 micrograms HA B/XXXXXX............................................... 45 micrograms HA B/XXXXXX............................................... 45 micrograms HA * produced by recombinant DNA technology using a baculovirus expression system in a continuous insect cell line that is derived from Sf9 cells of the fall armyworm, Spodoptera frugiperda. |
| Twinrix Adult | 1 dose (1 ml) contains: Hepatitis A virus (inactivated)¹,² 720 ELISA Units Hepatitis B surface antigen³,4 20 micrograms ¹Produced on human diploid (MRC-5) cells ²Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al³+ ³Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4Adsorbed on aluminium phosphate 0.4 milligrams Al³+ |
| Twinrix Paediatric | --¹ 1 dose (0.5 ml): Hepatitis A virus (inactivated)¹,² 360 ELISA Units Hepatitis B surface antigen³,⁴ 10 micrograms ¹Produced on human diploid (MRC-5) cells ²Adsorbed on aluminium hydroxide, hydrated 0.025 milligrams Al³+ ³Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology ⁴Adsorbed on aluminium phosphate 0.2 milligrams Al³+ |
| Varivax | powder and solvent for suspension for injection in pre-filled syringe |
| Vaxigrip | Vaxigrip suspеnsion for injection in pre-filled syringe |
| Vaxigrip Tetra | suspеnsion for injection in pre-filled syringe |
| Verorab | powder and solvent for suspension for injection |
| Zoonotic Influenza Vaccine Seqirus | --¹ Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strain: A/Astrakhan/3212/2020 (H5N8) - like strain (CBER-RG8A) (clade 2.3.4.4b) 7.5 micrograms** per 0.5 ml dose * propagated in fertilised hens’ eggs from healthy chicken flocks ** expressed in microgram haemagglutinin Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams |